1.
Bioorg Med Chem Lett
; 14(4): 1053-6, 2004 Feb 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15013022
RESUMO
On the basis of screening hits (1a,b), a series of selective, high affinity prostacyclin receptor antagonists was developed. The optimized lead compound 25d [(4,5-dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxybenzyl)phenyl]amine] had analgesic activity in the rat.